Promega GmbH 1. Juli 2021

NanoLuc® Binary Technology-based Assays for SARS-CoV-2 Research and Drug/Vaccine Development

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic. Understanding the biology and pathogenesis of 

SARS-CoV-2 is critical to accomplish the challenging task of developing effective anti-viral treatments and vaccines. 

 

In this webinar, we will introduce a selection of bioluminescent assays and molecular tools based on the versatile NanoLuc® Binary Technology (NanoBiT®). We will demonstrate how these assays allow for the investigation of various aspects of the SARS-CoV-2 life cycle and can be applied in the development of anti-viral drugs and vaccines.

 

You will learn:

 

•   About the principle and advantages of the NanoLuc® Binary Technology 

    (NanoBiT®)

•   How NanoBiT® supports the analysis of virus-host interactions

•   How to study antiviral activities of therapeutic antibodies against 

    SARS-CoV-2  


Wednesday, July 7th, 2021 at 10:00 am CEST


Register here

Services: Mit 2.000 Katalogprodukten bietet Promega ein breit gefächertes Portfolio an innovativen und qualitativ hochwertigen Reagenzie... [mehr]